CCO Podcasts
The Science of Integrase Strand Transfer Inhibitors: New Insights and Clinical Implications
|
|
Joseph J. Eron Jr., MD; Richard Haubrich, MD; Daniel R. Kuritzkes, MD; and Paul E. Sax, MD, discuss the science behind the use of integrase inhibitors, clinical studies of integrase inhibitors, and the role of these agents in managing HIV-infected patients.
Date posted: 10/22/2009
| Duration: 15:04
|
Studies of Integrase Inhibitors Across the Treatment Spectrum
|
|
Joseph J. Eron Jr., MD; Richard Haubrich, MD; Daniel R. Kuritzkes, MD; and Paul E. Sax, MD, discuss the science behind the use of integrase inhibitors, clinical studies of integrase inhibitors, and the role of these agents in managing HIV-infected patients.
Date posted: 10/22/2009
| Duration: 25:33
|
The Current Role of Integrase Inhibitors in Clinical Practice
|
|
Joseph J. Eron Jr., MD; Richard Haubrich, MD; Daniel R. Kuritzkes, MD; and Paul E. Sax, MD, discuss the science behind the use of integrase inhibitors, clinical studies of integrase inhibitors, and the role of these agents in managing HIV-infected patients.
Date posted: 10/22/2009
| Duration: 19:08
|
Case Discussions: Considerations of Using an Integrase Inhibitor in a Treatment-Naive Patient, as a Switch Agent, and in a Treatment-Experienced Patient
|
|
Joseph J. Eron Jr., MD; Richard Haubrich, MD; Daniel R. Kuritzkes, MD; and Paul E. Sax, MD, discuss the science behind the use of integrase inhibitors, clinical studies of integrase inhibitors, and the role of these agents in managing HIV-infected patients.
Date posted: 10/22/2009
| Duration: 34:46
|
Case 2: HIV-Infected Man With Many Years of Incomplete Virologic Suppression
|
|
Kimberly Y. Smith, MD, MPH, Daniel R. Kuritzkes, MD, and Andrew R. Zolopa, MD, consider the antiretroviral history and current presentation of this highly treatment-experienced patient and challenge you to create a suppressive regimen for him.
Date posted: 6/11/2009
|
Case 1: A Multidrug-Resistant HIV-Infected Man With Intermittent Virologic Suppression
|
|
Join Kimberly Y. Smith, MD, MPH, Daniel R. Kuritzkes, MD, and Andrew R. Zolopa, MD, as they guide you through the decision-making process for the construction of a new regimen for these highly treatment-experienced patients.
Date posted: 6/11/2009
|
When to Start
|
|
Joel E. Gallant, MD, MPH, reviews results from NA-ACCORD, the ART Cohort Collaboration, that provide additional data to consider when determining when to initiate antiretroviral therapy.
Date posted: 2/13/2009
| Duration: 7:48
|
Switch Studies From Lopinavir/Ritonavir to Raltegravir
|
|
Kimberly Y. Smith, MD, MPH, describes these interesting results from the SWITCHMRK trial.
Date posted: 12/31/2008
| Duration: 7:08
|
Recent Advances in PI Therapy
|
|
Charles B. Hicks, MD, reviews recent data from randomized clinical trials investigating the use of ritonavir-boosted PIs
Date posted: 12/31/2008
| Duration: 17:44
|
Selecting an Antiretroviral Regimen for a Woman Recently Diagnosed With HIV
|
|
Charles B. Hicks, MD, moderates a discussion among himself, Edwin DeJesus, MD, FACP, and W. David Hardy, MD, regarding treatment options for an antiretroviral-naive patient
Date posted: 12/31/2008
| Duration: 16:58
|
Case 2: Highly Experienced Patient Who Has Never Achieved Virologic Suppression
|
|
Date posted: 12/31/2008
| Duration: 25:46
|
Making Treatment Decisions for a Chronically Ill Patient With Virologic Failure of an Initial PI-Based Regimen
|
|
Charles B. Hicks, MD, moderates a discussion among himself, Edwin DeJesus, MD, FACP, and W. David Hardy, MD, on how best to manage the treatment of a patient with virologic failure of an initial PI-based regimen
Date posted: 12/31/2008
| Duration: 17:42
|
Management of an HIV-Infected Female With Dyslipidemia on a PI-Based Regimen
|
|
Charles B. Hicks, MD, moderates a discussion among himself, Edwin DeJesus, MD, FACP, and W. David Hardy, MD, regarding antiretroviral treatment options for a woman with dyslipidemia
Date posted: 12/31/2008
| Duration: 13:44
|
Management of an Antiretroviral-Experienced Patient With Low-Level Viremia and Availability of Multiple PIs With Suspected Activity
|
|
Charles B. Hicks, MD, moderates a discussion among himself, Edwin DeJesus, MD, FACP, and W. David Hardy, MD, regarding the use of PIs in a treatment-experienced patient
Date posted: 12/31/2008
| Duration: 16:21
|
Treatment of Hepatitis Coinfection
|
|
Bruce Polsky, MD, discusses the use of fixed-dose tenofovir/emtricitabine for the treatment of HIV/HBV-coinfected patients and the failure of high ribavirin doses to provide increased ribavirin exposure when given with erythropoietin.
Date posted: 10/30/2008
| Duration: 8:24
|
Metabolic Complications of HIV and ART
|
|
William G. Powderly, MD, discusses interesting data on bone metabolism from the SMART study and several key papers about diabetes in HIV-infected patients.
Date posted: 10/30/2008
| Duration: 8:55
|
Treatment of TB in HIV-Infected Patients
|
|
Sally Hodder, MD, reviews a promising study of TMC207, an investigational drug for treatment of tuberculosis, and also reports disappointing results of a study of isoniazid treatment in children in South Africa.
Date posted: 10/29/2008
| Duration: 5:04
|
Initiating Antiretroviral Therapy
|
|
Eric S. Daar, MD, gives an overview of several trials of antiretroviral-naive patients and discusses new information that may inform on when to start therapy.
Date posted: 10/28/2008
| Duration: 7:42
|
New Agents
|
|
Joseph J. Eron, Jr., MD, describes new data on the investigational maturation inhibitor bevirimat and entry inhibitor PRO 140 and discusses the reanalysis of data from the MERIT trial.
Date posted: 10/28/2008
| Duration: 13:39
|
Treatment-Experienced Patients
|
|
Paul E. Sax, MD, reviews real-world trials of newer agents in the treatment of antiretroviral patients
Date posted: 10/28/2008
| Duration: 7:01 MB
|
Timing and Choice of First-Line Antiretroviral Therapy
|
|
Joel E. Gallant, MD, MPH, reports on the phase III STARTMRK trial of raltegravir vs efavirenz in antiretroviral-naive patients and on the NA-ACCORD cohort study on when to start antiretroviral therapy.
Date posted: 10/27/2008
| Duration: 8:20
|
Antiretroviral Resistance and Viral Tropism
|
|
Daniel R. Kuritzkes, MD, discusses new data on raltegravir mechanism of action, resistance to integrase inhibitors, viral tropism, and prevalence of the K65R mutation in populations with subtype C virus.
Date posted: 10/27/2008
| Duration: 15:07
|
Management of Treatment-Experienced Patients
|
|
Sharon L. Walmsley, MSc, MD, FRCPC, reports on several analyses from clinical trials that inform on the assessment of activity of antiretroviral agents in treatment-experienced patients and the optimal construction of regimens for these patients.
Date posted: 10/27/2008
| Duration: 10:45
|
Antiretroviral Therapy in Treatment-Naive Patients
|
|
Anton L. Pozniak, MD, FRCP, reports on the 96-week results from the CASTLE, ARTEMIS, and HEAT clinical trials in treatment-naive patients as well as several analyses on the use of abacavir in patients with high HIV-1 RNA
Date posted: 10/26/2008
| Duration: 8:34
|
Expert Highlight: Late Breaker Sessions
|
|
Daniel R. Kuritzkes, MD, highlights clinically relevant data from key studies presented at the 2008 International AIDS Conference Late Breaker Sessions (13 minutes)
Date posted: 8/8/2008
| Duration: 12:39
|
Expert Highlight: Poster Recap
|
|
While on location at the 2008 International AIDS Conference, Pedro Cahn, MD, PhD, commented on the clinical implications of several studies presented at the conference.
Date posted: 8/7/2008
| Duration: 6:03
|
Expert Highlight: First-Line Therapy
|
|
Joel E. Gallant, MD, reviews clinically relevant data from presentations on first-line antiretroviral therapy from the 2008 International AIDS Conference (5 minutes)
Date posted: 8/7/2008
| Duration: 5:22
|
Expert Highlight: Resistance in Resource-Limited Settings
|
|
Anton L. Pozniak, MD, FRCP, reviews data from studies investigating antiretroviral resistance in resource-limited countries
Date posted: 8/7/2008
| Duration: 3:31
|
Expert Highlight: Women and HIV
|
|
Kathleen E. Squires, MD, recaps studies that will likely impact the management of HIV-infected women while she was on location at the 2008 International AIDS Conference.
Date posted: 8/7/2008
| Duration: 3:57
|
Expert Highlight: Newer Antiretrovirals
|
|
Kimberly Y. Smith, MD, MPH, discusses the efficacy and safety data from 3 studies presented at the 2008 International AIDS Conference, each investigating newer antiretroviral agents compared with efavirenz in treatment-naive patients.
Date posted: 8/6/2008
| Duration: 6:57
|
Expert Highlight: HIV Comorbidities
|
|
Jürgen K. Rockstroh, MD, discusses the results of key reports on HIV comorbidities from the 2008 International AIDS Conference, including the incidence and treatment of tuberculosis as well as hepatitis in HIV-coinfected patients
Date posted: 8/5/2008
| Duration: 10:12
|
Expert Highlight: HAART Complications
|
|
José Gatell, MD, provides an overview of presentations on the new IAS treatment guidelines, HAART-associated complications, and tuberculosis coinfection, and then speculates on the future of an HIV vaccine.
Date posted: 8/4/2008
| Duration: 8:00
|
Expert Highlight: IAC Preview 2
|
|
Mauro Schechter, MD, PhD, highlights what he expects to be some of the most important presentations at this year’s International AIDS Conference.
Date posted: 8/3/2008
| Duration: 2:31
|
Expert Highlight: IAC Preview 1
|
|
Sharon L. Walmsley, MSc, MD, FRCPC, gives an overview of the top issues and studies that will be presented at this year’s International AIDS Conference.
Date posted: 8/3/2008
| Duration: 3:23
|
Treatment Considerations for a Highly Treatment–Experienced Patient With No Fully Active PIs
|
|
Charles B. Hicks, MD, moderates a discussion among himself, Edwin DeJesus, MD, FACP, and W. David Hardy, MD, regarding the treatment options for a patient with no fully active PIs
Date posted: 7/3/2008
| Duration: 16:22
|
Case 1: Highly Experienced Patient With Virologic Rebound on Many Successive Regimens
|
|
Join Kimberly Y. Smith, MD, MPH; Sally Hodder, MD; and Andrew R. Zolopa, MD, as they guide you through the decision-making process for the construction of a new regimen for this highly treatment–experienced patient.
Date posted: 6/30/2008
| Duration: 33:07
|
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
|
Featured Content
View new HIV data from the San Francisco meeting and listen to audio Expert Highlights.
Explore the latest issues in HIV mgmt through streaming video & downloadable Podcasts.
Get fast and reliable answers to your HIV treatment questions at the point of care.
|